|
1
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:683–691. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Prenen H, Tejpar S and Van Cutsem E:
Impact of molecular markers on treatment selection in advanced
colorectal cancer. Eur J Cancer. 45 suppl 1:S70–S78. 2009.
View Article : Google Scholar
|
|
3
|
Bokemeyer C, van Cutsem E, Rougier P,
Ciardiello F, Heeger S, Schlichting M, Celik I and Köhne CH:
Addition of cetuximab to chemotherapy as first-line treatment for
KRAS wild-type metastatic colorectal cancer: Pooled analysis of the
CRYSTAL and OPUS randomised clinical trials. Eur J Cancer.
48:1466–1475. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Douillard JY, Oliner KS, Siena S,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Panitumumab-FOLFOX4 treatment and RAS mutations
in colorectal cancer. N Engl J Med. 369:1023–1034. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stintzing S, Jung A, Rosssius L and
Heinemann V: Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A
randomized phase III study of Folfiri plus cetuximab or bevacizumab
as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic
colorectal cancer (mCRC) patients. Eur J Cancer. 49 suppl
3:Abstract 17. 2013.
|
|
6
|
Schwartzberg LS, Rivera F, Karthaus M,
Fasola G, Canon JL, Yu H, Oliner KS and Go WY: Analysis of
KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6
plus panitumumab (pmab) or bevacizumab (bev) as first-line
treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic
colorectal cancer (mCRC). J Clin Oncol. 13 suppl 3:abstr 3631.
2013.
|
|
7
|
de Roock W, De Vriendt V, Normanno N,
Ciardiello F and Tejpar S: KRAS, BRAF, PIK3CA, and PTEN mutations:
Implications for targeted therapies in metastatic colorectal
cancer. Lancet Oncol. 12:594–603. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gerlinger M, Rowan AJ, Horswell S, Larkin
J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A,
Tarpey P, et al: Intratumor heterogeneity and branched evolution
revealed by multiregion sequencing. N Engl J Med. 366:883–892.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kopetz S, Overman MJ, Chen K,
Lucio-Eterovic AK, Kee BK, Fogelman DR, Dasari A, Raghav KPS,
Sanchez EV, Phillips J, et al: Mutation and copy number discordance
in primary versus metastatic colorectal cancer (mCRC). J Clin
Oncol. 32 Suppl: abstr 3509:5S2014.
|
|
10
|
Adua D, Altimari A, Gruppioni E, Ercolani
G, Llimpe FLR, Fabio FD, Fiorentino M, Pinna AD, Pinto C; Medical
Oncology Unit, ; S. Orsola-Malpighi Hospital, Bologna, Italy, ; et
al: Molecular evaluation of primary tumor (PT) and synchronous
liver metastasis in colorectal cancer (srLmCRC) patients after
cetuximab-based chemotherapy. J Clin Oncol. 32 Suppl:abstr 3624.
5S2014.
|
|
11
|
Mao C, Wu XY, Yang ZY, Threapleton DE,
Yuan JQ, Yu YY and Tang JL: Concordant analysis of KRAS BRAF,
PIK3CA mutations, and PTEN expression between primary colorectal
cancer and matched metastases. Sci Rep. 5:80652015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sartore-Bianchi A, Di Nicolantonio F,
Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani
T, Marrapese G, Mazzucchelli L, et al: Multi-determinants analysis
of molecular alterations for predicting clinical benefit to
EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One.
4:e72872009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Normanno N, Rachiglio AM, Lambiase M,
Martinelli E, Fenizia F, Esposito C, Roma C, Troiani T, Rizzi D,
Tatangelo F, et al: Heterogeneity of KRAS NRAS, BRAF and PIK3CA
mutations in metastatic colorectal cancer and potential effects on
therapy in the CAPRI GOIM trial. Ann Oncol. 26:1710–174. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ciardiello F, Normanno N, Maiello E,
Martinelli E, Troiani T, Pisconti S, Giuliani F, Barone C, Cartenì
G, Rachiglio AM, et al: Clinical activity of FOLFIRI plus cetuximab
according to extended gene mutation status by next-generation
sequencing: Findings from the CAPRI-GOIM trial. Ann Oncol.
25:1756–1761. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ciardiello F and Normanno N: HER2
signaling and resistance to the anti-EGFR monoclonal antibody
cetuximab: A further step toward personalized medicine for patients
with colorectal cancer. Cancer Discov. 1:472–474. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Misale S, Di Nicolantonio F,
Sartore-Bianchi A, Siena S and Bardelli A: Resistance to anti-EGFR
therapy in colorectal cancer: From heterogeneity to convergent
evolution. Cancer Discov. 4:1269–1280. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang ZY, Wu XY, Huang YF, Di MY, Zheng DY,
Chen JZ, Ding H, Mao C and Tang JL: Promising biomarkers for
predicting the outcomes of patients with KRAS wild-type metastatic
colorectal cancer treated with anti-epidermal growth factor
receptor monoclonal antibodies: A systematic review with
meta-analysis. Int J Cancer. 133:1914–1925. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guinney J, Ferté C, Dry J, McEwen R,
Manceau G, Kao KJ, Chang KM, Bendtsen C, Hudson K, Huang E, et al:
Modeling RAS phenotype in colorectal cancer uncovers novel
molecular traits of RAS dependency and improves prediction of
response to targeted agents in patients. Clin Cancer Res.
20:265–272. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Montagut C, Dalmases A, Bellosillo B,
Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S,
Tsai SP, et al: Identification of a mutation in the extracellular
domain of the epidermal growth factor receptor conferring cetuximab
resistance in colorectal cancer. Nat Med. 18:221–223. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Arena S, Bellosillo B, Siravegna G,
Martínez A, Cañadas I, Lazzari L, Ferruz N, Russo M, Misale S,
González I, et al: Emergence of multiple EGFR extracellular
mutations during cetuximab treatment in colorectal cancer. Clin
Cancer Res. 21:2157–2166. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
van Emburgh BO, Arena S, Siravegna G,
Lazzari L, Crisafulli G, Corti G, Mussolin B, Baldi F, Buscarino M,
Bartolini A, et al: Acquired RAS or EGFR mutations and duration of
response to EGFR blockade in colorectal cancer. Nat Commun.
7:136652016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Montagut C, Siravegna G and Bardelli A:
Liquid biopsies to evaluate early therapeutic response in
colorectal cancer. Ann Oncol. 26:1525–1527. 2015. View Article : Google Scholar : PubMed/NCBI
|
